Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program
Humana and Monogram Health have announced a significant expansion of their comprehensive kidney care program. The expansion extends in-home treatment access for Medicare Advantage members with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) across Alabama, Louisiana, Mississippi, Tennessee, and now Georgia.
The collaboration focuses on value-based care, enabling earlier interventions and reaching new patients, particularly in Georgia. The program provides evidence-based nephrology and multispecialty care in patients' homes, addressing not only kidney disease but also underlying conditions like hypertension, diabetes, and metabolic disorders.
This initiative is particularly significant as chronic kidney disease affects approximately 37 million Americans, with nearly 15% of the Medicare-aged population in Alabama, Tennessee, and Louisiana having CKD - among the highest prevalence rates nationwide. The program aims to address the notable gap in specialized care access, as most CKD patients have never consulted a nephrologist.
Humana e Monogram Health hanno annunciato un'importante espansione del loro programma completo di assistenza per i reni. L'espansione amplia l'accesso ai trattamenti a domicilio per i membri di Medicare Advantage con malattia renale cronica (CKD) e malattia renale terminale (ESKD) in Alabama, Louisiana, Mississippi, Tennessee e ora anche in Georgia.
La collaborazione si concentra sulla cura basata sul valore, consentendo interventi precoci e raggiungendo nuovi pazienti, in particolare in Georgia. Il programma offre assistenza nefrologica e multispecialistica basata su prove a domicilio dei pazienti, affrontando non solo la malattia renale, ma anche condizioni sottostanti come ipertensione, diabete e disturbi metabolici.
Questa iniziativa è particolarmente significativa poiché la malattia renale cronica colpisce circa 37 milioni di americani, con quasi il 15% della popolazione di età Medicare in Alabama, Tennessee e Louisiana che presenta CKD - tra i tassi di prevalenza più elevati a livello nazionale. Il programma mira a colmare il notevole divario nell'accesso alla cura specializzata, poiché la maggior parte dei pazienti con CKD non ha mai consultato un nefrologo.
Humana y Monogram Health han anunciado una expansión significativa de su programa integral de atención renal. La expansión amplía el acceso al tratamiento en casa para los miembros de Medicare Advantage con enfermedad renal crónica (CKD) y enfermedad renal en etapa terminal (ESKD) en Alabama, Louisiana, Mississippi, Tennessee y ahora Georgia.
La colaboración se centra en la atención basada en el valor, lo que permite intervenciones más tempranas y el alcance de nuevos pacientes, particularmente en Georgia. El programa proporciona atención nefrológica y multispecialidad basada en evidencia en los hogares de los pacientes, abordando no solo la enfermedad renal, sino también condiciones subyacentes como hipertensión, diabetes y trastornos metabólicos.
Esta iniciativa es particularmente significativa, ya que la enfermedad renal crónica afecta a aproximadamente 37 millones de estadounidenses, con casi el 15% de la población de edad Medicare en Alabama, Tennessee y Louisiana que presenta CKD - entre las tasas de prevalencia más altas a nivel nacional. El programa tiene como objetivo abordar la notable brecha en el acceso a la atención especializada, ya que la mayoría de los pacientes con CKD nunca han consultado a un nefrólogo.
휴마나와 모노그램 헬스는 포괄적인 신장 관리 프로그램의 중요한 확장을 발표했습니다. 이 확장은 알라바마, 루이지애나, 미시시피, 테네시, 그리고 이제 조지아에서 만성 신장 질환(CKD) 및 말기 신장 질환(ESKD)을 앓고 있는 메디케어 어드밴티지 회원을 위한 가정 치료 접근을 확대합니다.
이 협력은 가치 기반 치료에 중점을 두어 조기 개입을 가능하게 하고 특히 조지아에서 새로운 환자에게 도달하는 데 도움을 줍니다. 이 프로그램은 환자의 가정에서 근거 기반의 신장학 및 다전문 치료를 제공하며, 신장 질환뿐만 아니라 고혈압, 당뇨병 및 대사 장애와 같은 기저 질환도 다룹니다.
이 이니셔티브는 만성 신장 질환이 약 3,700만 명의 미국인에게 영향을 미치며, 알라바마, 테네시, 루이지애나의 메디케어 연령 인구의 거의 15%가 CKD를 앓고 있어 전국적으로 가장 높은 유병률을 보이는 점에서 특히 중요합니다. 이 프로그램은 대부분의 CKD 환자가 신장 전문의를 한 번도 상담한 적이 없다는 점에서 전문 치료 접근의 현저한 격차를 해소하는 것을 목표로 합니다.
Humana et Monogram Health ont annoncé une expansion significative de leur programme complet de soins rénaux. L'expansion élargit l'accès au traitement à domicile pour les membres de Medicare Advantage atteints de maladie rénale chronique (CKD) et de maladie rénale en phase terminale (ESKD) dans l'Alabama, la Louisiane, le Mississippi, le Tennessee, et maintenant la Géorgie.
La collaboration se concentre sur des soins basés sur la valeur, permettant des interventions plus précoces et atteignant de nouveaux patients, en particulier en Géorgie. Le programme fournit des soins en néphrologie et en spécialités multiples basés sur des preuves au domicile des patients, abordant non seulement la maladie rénale, mais aussi des conditions sous-jacentes telles que l'hypertension, le diabète et les troubles métaboliques.
Cette initiative est particulièrement significative car la maladie rénale chronique touche environ 37 millions d'Américains, avec près de 15 % de la population âgée de Medicare en Alabama, au Tennessee et en Louisiane ayant une CKD - l'un des taux de prévalence les plus élevés du pays. Le programme vise à combler le fossé notable dans l'accès aux soins spécialisés, car la plupart des patients atteints de CKD n'ont jamais consulté un néphrologue.
Humana und Monogram Health haben eine bedeutende Erweiterung ihres umfassenden Nierenpflegeprogramms angekündigt. Die Erweiterung verbessert den Zugang zu häuslicher Behandlung für Medicare Advantage-Mitglieder mit chronischer Nierenerkrankung (CKD) und terminaler Nierenerkrankung (ESKD) in Alabama, Louisiana, Mississippi, Tennessee und jetzt auch in Georgia.
Die Zusammenarbeit konzentriert sich auf wertbasierte Versorgung, die frühere Interventionen ermöglicht und neue Patienten erreicht, insbesondere in Georgia. Das Programm bietet evidenzbasierte Nephrologie und multidisziplinäre Versorgung im Zuhause der Patienten und behandelt nicht nur Nierenerkrankungen, sondern auch zugrunde liegende Erkrankungen wie Bluthochdruck, Diabetes und Stoffwechselstörungen.
Diese Initiative ist besonders bedeutend, da chronische Nierenerkrankung etwa 37 Millionen Amerikaner betrifft, wobei fast 15 % der Medicare-alter Bevölkerung in Alabama, Tennessee und Louisiana an CKD leiden – eine der höchsten Prävalenzraten im ganzen Land. Das Programm zielt darauf ab, die bemerkenswerte Lücke im Zugang zur spezialisierten Versorgung zu schließen, da die meisten CKD-Patienten nie einen Nephrologen konsultiert haben.
- Expansion into new geographic market (Georgia)
- Addresses large market opportunity (37 million Americans with CKD)
- Targets high-prevalence regions (15% Medicare population in key states)
- Comprehensive care approach including underlying conditions
- None.
Insights
This expansion of Humana's partnership with Monogram Health represents a strategically significant move in the competitive Medicare Advantage market. The program targets five southeastern states with some of the highest CKD prevalence rates, where approximately 15% of the Medicare-aged population suffers from chronic kidney disease.
The financial implications are substantial. By focusing on early intervention and in-home care, Humana positions itself to potentially reduce costly emergency room visits and hospitalizations associated with CKD progression. The value-based care model, which emphasizes prevention and comprehensive disease management, typically results in 20-30% lower healthcare costs compared to traditional fee-for-service models.
This expansion strengthens Humana's competitive positioning in the Medicare Advantage market through several mechanisms:
- Enhanced member retention through improved care quality and convenience
- Potential reduction in medical loss ratio through better disease management
- Increased attractiveness to new Medicare Advantage members in target markets
- Strategic alignment with CMS's push toward value-based care models
The focus on traditionally underserved populations and in-home care delivery is particularly noteworthy as it addresses both clinical and social determinants of health. This comprehensive approach typically leads to better health outcomes and higher star ratings, which directly impact reimbursement rates and market competitiveness.
Value-based care focuses on the collaboration and coordination of all aspects of a patient’s care, and this expansion enables earlier interventions to a larger population in existing markets while also reaching new patients statewide in
"Providing access to quality care for our Medicare Advantage members with complex health conditions is crucial," said Alan Stewart, President of Humana's Medicare East Division. "Our collaboration with Monogram enables us to enhance support for our members with chronic kidney disease and end-stage kidney disease to help improve health outcomes."
“We don’t just treat the manifestation of the disease, but the conditions that cause kidney disease, like hypertension, diabetes, and metabolic disorders,” said Michael Uchrin, Chief Executive Officer and Co-Founder of Monogram Health. “It is our privilege to work together with Humana to deliver quality, specialist-driven care to their members where they are most comfortable – in their homes.”
Chronic kidney disease affects approximately 37 million Americans, many of whom also struggle with multiple chronic conditions like diabetes, high blood pressure, and heart disease. A majority of CKD patients have never seen a nephrologist, revealing a considerable deficiency in specialized care access. This is particularly relevant in the states Monogram covers through this agreement with Humana – as nearly
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we strive to make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
About Monogram Health
Monogram Health is the leading value-based multispecialty provider of in-home evidence-based care and benefit management services for patients living with polychronic conditions, notably chronic kidney and end-stage kidney disease. The company deploys an innovative in-home care delivery model and technology-driven array of evidence-based clinical services, including complex case and disease management, utilization management, and medication therapy management to transform the way health care is delivered for those with polychronic conditions. This innovative model of care has been shown to dramatically improve patient outcomes and quality of life while reducing medical costs across the health care continuum. Based in
Disclaimer: Other providers are available in the Humana network. Provider may also contract with other plan sponsors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213062933/en/
Lisa Dimond
Humana Corporate Communications
ldimond@humana.com
Holly Talbert
Monogram Health Corporate Communications
holly.talbert@monogramhealth.com
Source: Humana Inc.
FAQ
What states are covered in Humana's expanded kidney care program with Monogram Health?
What conditions does Humana's kidney care program with Monogram Health treat?
What percentage of Medicare-aged population has CKD in Humana's key service states?
How many Americans are affected by chronic kidney disease according to Humana's announcement?
What type of care delivery model does Humana's kidney care program use?
